Indivumed GmbH. (1/26/21). "Press Release: Indivumed Appoints Roald Forsberg as New Chief Business Officer". Hamburg.

	Organisation	Indivumed GmbH
	Group	Indivumed (Group)
	Organisation 2	2cureX ApS
	Group	2cureX (Group)
	Product	IndivuType multi-omics cancer patient database
	Product 2	genomic technology
	Person	Forsberg, Roald (Indivumed 202101– CBO joined 2019 formerly CLC bio 200806 Director Scientific Solutions)
	Person 2	Andreu, Fernando (2curex 202101– before Indivumed + Sysmex Inostics)

Indivumed appoints Dr. Roald Forsberg as Chief Business Officer and Head of the IndivuType Business Unit. Forsberg joined Indivumed in 2019 as Vice President, Oncology Informatics and Advanced Analytics for IndivuType and established Indivumed’s highly competitive AI-data analytics capabilities to utilize multi-omics data for R&D in personalized oncology.

Prior to joining Indivumed, Forsberg served in several executive leadership positions at bioinformatics and biotechnology companies, as well as in management consulting. He has driven deep-tech entrepreneurship and innovation and worked extensively with the creation and successful implementation of digital business models in the life-science sector.

“It has been a privilege to be part of the process in building up the IndivuType multi-omics database and our AI-advanced analytics platform,” said Forsberg. “As our discovery solution is now ready for full commercial engagement, I am most excited to be taking on the overall leadership of securing the further development and also commercial success of IndivuType. We have built the most powerful discovery engine for personalized medicine that the world has ever seen, and I look forward to bringing this to the forefront of the battle against cancer together with our team.”

Forsberg succeeds Fernando Andreu, who led the IndivuType Business Unit during its early phase. Andreu has accepted an offer to become CEO of a publicly listed company.

“We wish Fernando all the best for this exciting new position and thank him for his great work in establishing our groundbreaking IndivuType multi-omics database,” said Prof. Dr. Hartmut Juhl, Founder and CEO of Indivumed Group. “We are proud that Roald, who has a tremendous background of combining scientific excellence with a comprehensive experience in digital business could fill this critical position. We are grateful and excited that he accepted the offer of becoming Indivumed’s new CBO and Head of the IndivuType Business Unit.

Record changed: 2023-06-05